Wyeth loses Prempro case in Little Rock
LITTLE ROCK, Ark. A federal jury has ruled in favor of a woman who accused Wyeth Pharmaceuticals of negligence when she got breast cancer after taking the company’s hormone replacement therapy, according to the Associated Press.
Jurors for the lawsuit, which took place in the U.S. District Court in Little Rock, began deliberating last week and came to the decision that Wyeth inadequately warned the woman, Donna Scroggin, that Prempro and Premarin carried an increase risk of breast cancer.
Jurors recommended that Scroggin receive $2.75 million. The punitive phase of the trial is to begin March 3.
This is one of about 5,300 lawsuits that Wyeth is facing regarding the drugs Prempro and Premarin. A judge in Nevada earlier in the week reduced a $134 million award in a case in Reno to $58 million, split between three women.
FDA to closer scrutinize consumer drug advertisements
WASHINGTON The Food and Drug Administration’s current budget for reviewing consumer drug advertisements is larger this year than the previous five years combined, according to USA TODAY.
The FDA received $6.1 million for the current fiscal year to check the fairness and accuracy of consumer drug ads. That’s up from $2.2 million the previous year and $1 million the year before.
The FDA says it plans to hire more people so it can review more ads. It has 13 workers devoted to policing direct-to-consumer ad materials, six of which are primary reviewers. Last year, the FDA received 12,616 drug ad materials.
The FDA has been so overwhelmed by drug industry ad materials that only a “small portion” is reviewed, the Government Accountability Office said in a 2006 report. The FDA often didn’t declare consumer ads false or misleading until after ad campaigns were over, the GAO said.
President Bush’s proposed 2009 budget calls for $14 million from user fees to fund 27 FDA positions devoted to the consumer-ad-review program. In exchange, the FDA would review TV drug ads within 45 days of getting them from drugmakers — which is faster than many reviews occur now — and before the ads are seen by millions of viewers.
HOUSTON The Professional Compounding Centers of America has named John Herr its recipient of the Dr. M. George Webber Compounding Pharmacist of the Year, an award that is presented annually to an independent pharmacist who has demonstrated service excellence to patients, healthcare providers and pharmacy colleagues.
L. David Sparks, PCCA’s president/chief executive officer, presented the award to Herr during the company’s International Seminar held in Houston in January 2008. “This year, we recognize a pharmacist who has become one of our profession’s most respected compounders,” Sparks declared. “His colleagues appreciate his generosity and willingness to share and network with them. His pharmacy staff respects his dedication to compounding, compassion for patients and concern for their own well being as his employees. His patients and prescribers appreciate his ability to solve specific medication needs in a high-quality manner.”
Herr has been a registered pharmacist for more than 20 years, and has been an owner of Town & Country Pharmacy since 1999. He is the recipient of several recognition awards for his outstanding service in his practice of the art and science of pharmacy compounding, including the New Jersey Hospice and Palliative Care Organization’s 1998 Hospice Team Award for outstanding leadership as a Hospice Pharmacist.